Shares of HCA Healthcare Inc (NYSE:HCA) have been assigned a consensus rating of “Buy” from the twenty-four brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $143.57.
HCA has been the topic of a number of research analyst reports. Citigroup raised their target price on HCA Healthcare from $136.00 to $156.00 and gave the company a “buy” rating in a report on Thursday, October 11th. Jefferies Financial Group raised their target price on HCA Healthcare from $155.00 to $158.00 and gave the company a “buy” rating in a report on Wednesday, October 31st. Credit Suisse Group raised their target price on HCA Healthcare from $156.00 to $165.00 and gave the company an “outperform” rating in a report on Thursday, November 1st. Argus raised their target price on HCA Healthcare from $150.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 6th. Finally, Zacks Investment Research downgraded HCA Healthcare from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th.
In related news, insider Michael S. Cuffe sold 4,943 shares of the stock in a transaction on Friday, November 9th. The stock was sold at an average price of $141.90, for a total value of $701,411.70. Following the transaction, the insider now owns 33,240 shares of the company’s stock, valued at $4,716,756. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Kathryn A. Torres sold 820 shares of the stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $142.36, for a total value of $116,735.20. Following the completion of the transaction, the senior vice president now directly owns 4,237 shares in the company, valued at approximately $603,179.32. The disclosure for this sale can be found here. Insiders have sold a total of 16,763 shares of company stock valued at $2,346,147 in the last quarter. Company insiders own 2.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC raised its position in shares of HCA Healthcare by 98.7% in the third quarter. FMR LLC now owns 10,907,407 shares of the company’s stock valued at $1,517,438,000 after buying an additional 5,419,134 shares during the last quarter. AQR Capital Management LLC raised its stake in HCA Healthcare by 433.7% in the third quarter. AQR Capital Management LLC now owns 1,293,241 shares of the company’s stock valued at $179,916,000 after buying an additional 1,050,940 shares during the period. Massachusetts Financial Services Co. MA raised its stake in HCA Healthcare by 98.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,767,715 shares of the company’s stock valued at $245,925,000 after buying an additional 876,226 shares during the period. Point72 Asset Management L.P. increased its stake in shares of HCA Healthcare by 547.2% during the third quarter. Point72 Asset Management L.P. now owns 873,660 shares of the company’s stock worth $121,544,000 after purchasing an additional 738,660 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of HCA Healthcare by 213.7% during the third quarter. Acadian Asset Management LLC now owns 645,679 shares of the company’s stock worth $89,830,000 after purchasing an additional 439,826 shares during the period. Institutional investors and hedge funds own 69.80% of the company’s stock.
Shares of HCA Healthcare stock traded down $1.53 on Tuesday, hitting $133.01. The company’s stock had a trading volume of 23,710 shares, compared to its average volume of 1,347,444. HCA Healthcare has a 52-week low of $90.06 and a 52-week high of $147.42. The firm has a market capitalization of $46.30 billion, a PE ratio of 20.24, a P/E/G ratio of 1.09 and a beta of 0.69.
HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, October 30th. The company reported $2.16 EPS for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.23. HCA Healthcare had a net margin of 6.82% and a negative return on equity of 73.71%. The company had revenue of $11.45 billion during the quarter, compared to the consensus estimate of $11.29 billion. During the same quarter in the prior year, the company posted $1.13 EPS. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, research analysts forecast that HCA Healthcare will post 9.35 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, December 28th. Shareholders of record on Monday, December 3rd were paid a dividend of $0.35 per share. The ex-dividend date of this dividend was Friday, November 30th. This represents a $1.40 dividend on an annualized basis and a yield of 1.05%. HCA Healthcare’s dividend payout ratio (DPR) is currently 21.24%.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.